Biotech News
Related news
ZURAZura Bio2026-06-29 11:30 EST
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
ZURAZura Bio2026-08-21 23:57 EST
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INMBINmune Bio2026-07-30 11:00 EST
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
CABACabaletta Bio2026-06-03 11:00 EST
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
HCWBHCW Biologics2026-08-14 19:15 EST
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
CUECue Biopharma Inc2026-07-13 12:30 EST
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
AVTXAvalo Therapeutics2026-06-23 11:00 EST
Avalo Therapeutics Appoints Ron Philip to Board of Directors
ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
GRIGRI Bio2026-08-24 14:05 EST
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
SABSSAB Biotherapeutics2026-08-06 11:30 EST
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
Zura Bio
Autoimmune and Inflammatory Diseases Zura Bio develops biologics for serious autoimmune and inflammatory diseases, emphasizing combinations of validated immune pathways in single molecules. Tibulizumab Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF. The dual mechanism targets inflammatory and B-cell...
Recent company news
ZURAZura Bio2026-08-21 23:57 EST
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ZURAZura Bio2026-08-11 11:30 EST
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
ZURAZura Bio2026-06-29 11:30 EST
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
ZURAZura Bio2026-05-14 11:30 EST
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ZURAZura Bio2026-05-13 11:30 EST
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
Stock data
- Close
- 5.85 USD
- Market cap
- 389.01M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States